About: Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $16.70 (-4.95%)
CTNMNASDAQContineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock share price
CTNM price activity
Last Price
$16.700
Change (24hr)
-0.87 USD (-4.95%)
Volume
320.26K
Volume (4w avg)
-
Open
$17.38
Day Range
$16.50 - $17.71
Previous Close
$17.57
Last Trade
04 Sep, 8:00 pm GMT+0
Delayed
04 Sep, 8:00 pm GMT+0
CTNM price performance
Delayed
04 Sep, 8:00 pm GMT+0
CTNM Market Signals